SCHEMBL6318683

SCHEMBL6318683

NC(=O)c1c(-c2ccsc2)noc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 3/20 0.50
RET P07949 1/20 0.47
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
TDO2 P48775 1/20 0.43
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
CHEK2 O96017 3/20 0.40
CHEK1 O14757 1/20 0.39
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38
CA2 P00918 4/20 0.36
CA1 P00915 3/20 0.36
CA4 P22748 2/20 0.36
CA7 P43166 2/20 0.36
FLT4 P35916 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317187 0.88 IKBKB (0.43) IKBKBRETMEN1GAAKMT2A
SCHEMBL6314872 0.80 KMT2A (0.50) MEN1GAAKMT2AALDH1A1LMNA
SCHEMBL6317807 0.79 CA1 (0.60) ALDH1A1LMNACA2CA1CA4
SCHEMBL6316517 0.77 CA1 (0.52) GAAALDH1A1RAB9ACA2CA1
SCHEMBL6316792 0.76 RET (0.41) IKBKBRETMEN1GAAKMT2A
SCHEMBL28753358 0.76 NPC1 (0.42) IKBKBRETMEN1KMT2ATDO2
SCHEMBL6316757 0.76 ALDH1A1 (0.45) ALDH1A1MAPTLMNARAB9ACA2
SCHEMBL6318511 0.76 GAA (0.47) GAAKMT2AALDH1A1MAPTLMNA
SCHEMBL27609932 0.76 PRKCZ (0.43) MEN1GAAKMT2AALDH1A1MAPT
SCHEMBL6316187 0.75 KIT (0.46) RETMEN1GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 IKBKB 149/4885RET 768/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.